Navigation Links
Fovea Pharmaceuticals Receives Orphan Drug Designation from EC for RdCVF for the Treatment of Retinitis Pigmentosa
Date:1/7/2008

PARIS, Jan. 7 /PRNewswire/ -- Fovea Pharmaceuticals SA, which, last December 2007, raised $44M in a Series B financing, today announced that its product, Recombinant human rod-derived cone viability factor (rh-RdCVF), has received designation as Orphan Medicinal Product from the European Commission, following the positive opinion from the European Agency for the Evaluation of Medicinal Products (EMEA) Committee for Orphan Medicinal Product (COMP) for the treatment of retinitis pigmentosa, a genetic disease leading to progressive loss of vision. Fovea is currently conducting pre-clinical studies of RdCVF and has demonstrated efficacy in animal model of the disease.

Orphan drug designation would entitle Fovea to exclusive marketing rights in the European countries for ten years should Fovea be the first company to receive marketing approval for this type of therapeutic drug product. In addition, the designation would allow Fovea to apply for research funding, tax credits for certain research expenses, and protocol assistance. Similar orphan drug designation is currently being assessed in the USA by the Food and Drug Administration (FDA).

"We are pleased to have received this orphan drug designation for RdCVF in the treatment of retinitis pigmentosa," said Bernard Gilly, Chairman and Chief Executive Officer of Fovea. "This designation is a recognition of the quality of our work and will also provide us with financial and regulatory benefits in addition to market exclusivity."

In a study on animal model of the disease performed at INSERM U592 in Paris (Pr. Jose Sahel's team) RdCVF was shown to improve the survival and the functionality of retinal cone cells that are responsible for central vision and that are degenerating in patients suffering from this disease. Fovea is conducting further studies to produce RdCVF and plans to start clinical trials in 2009.

About Retinitis Pigmentosa

RP is a long lasting disease that slowly evol
'/>"/>

SOURCE Fovea Pharmaceuticals SA
Copyright©2008 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3

Related medicine technology :

1. VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation
2. Jazz Pharmaceuticals, Inc. Announces Receipt of FDA Orphan Drug Designation for Recurrent Acute Repetitive Seizures Product Candidate
3. Idenix Pharmaceuticals Provides Update on Hepatitis C Pipeline at JP Morgan Healthcare Conference
4. Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury
5. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
6. QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM) (ospemifene) to Treat Postmenopausal Vaginal Syndrome
7. Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program
8. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
9. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis
10. Celator(R) Pharmaceuticals Reports CPX-351 Shows Anti-Cancer Activity in Leukemia Patients
11. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...wire-FirstCall/--ThoratecCorporation(Nasdaq: THOR ...upporttherapiestosave,supportandrestorefailinghear...alPiperJaffrayHealthCareConferenceonTuesday,Decemb...hieffinancialofficer,willprovideanupdateonthecompa....,PacificStandardTime). ,, Thepresentationwillb...
(Date:11/24/2009)...--PharmaceuticalInstitute,aleadingproviderofspecia...chindustry,todayannouncedthelaunchofanewe-courseti...ace e-courseisthenewestadditiontothecompany,s Mana...esofe-coursesdesignedtofillthecriticalneedforbasic...fessionals. ,, Thenewthreemodule HospitalMarket...
(Date:11/24/2009)...bitBiosciencesCorporationannouncedtodaythattherewi...ondgenerationFLT3inhibitor,inAMLatthe51stAmericanS...rleans,LA,December5-8,2009.Anoralpresentationwillh...apysafetystudyinadultswithacutemyeloidleukemia(AML...uatingtheeffectofAC220monotherapyandincombinationw...
Breaking Medicine Technology:Pharmaceutical Institute Launches New Training Resource Focused on the Hospital Marketplace 2Ambit Biosciences Corporation Announces Presentations Profiling AC220 Clinical and Non-Clinical Data at 51st American Society of Hematology Annual Meeting 2Ambit Biosciences Corporation Announces Presentations Profiling AC220 Clinical and Non-Clinical Data at 51st American Society of Hematology Annual Meeting 3Ser Padres Joins Forces with la Doctora Alizas VidaySalud com to Offer the Hispanic Community Unprecedented Online Health Related Content in Spanish 49632 1Ser Padres Joins Forces with la Doctora Alizas VidaySalud com to Offer the Hispanic Community Unprecedented Online Health Related Content in Spanish 49632 2Ser Padres Joins Forces with la Doctora Alizas VidaySalud com to Offer the Hispanic Community Unprecedented Online Health Related Content in Spanish 49632 3DIA Annual Meeting Attendees Invited to Participate in Electronic Data Capture 28EDC 29 Clinical Trial Survey 4626 1DIA Annual Meeting Attendees Invited to Participate in Electronic Data Capture 28EDC 29 Clinical Trial Survey 4626 2Unspoken memories of Holocaust survivors find silent and nonpathological expression 49625 1Unspoken memories of Holocaust survivors find silent and nonpathological expression 49625 2
...ax Will Remain the NSTEMI Market Share Leader Thro...Resources , , WALTHAM, Mass., Feb. 25 Decision R...advisory firms for pharmaceutical and healthcare i...of mortality at 30 days is the attribute that most...cisions in non-ST elevation myocardial infarction ...
...res and infections of the bone are among most seri...Severe musculoskeletal conditions in children incl... as slipped epiphysis, and elbow fractures. These ...mplications if children are not treated properly a...leased today at the 2009 Annual Meeting of the Am...
Other Medicine Technology:Angiomax Will Retain Decision Resources' Proprietary Clinical Gold Standard Status Over Current and New Therapies, Including Recently-Approved Efient, for the Treatment of NSTEMI 2Angiomax Will Retain Decision Resources' Proprietary Clinical Gold Standard Status Over Current and New Therapies, Including Recently-Approved Efient, for the Treatment of NSTEMI 3Children and Orthopaedic Surgical Emergencies 2Children and Orthopaedic Surgical Emergencies 3
(Date:11/25/2009)...r basketball organization has selected a full rost...apy, technology, and learning as part of their vis...t Center. After a year of research and evaluation,...aquatic training; the selection of flagship hydrot...HydroWorx 2000 Series, an elite training tool, pac...
(Date:11/25/2009)...eamHealer,s GlobalIntentionHealsProjectprovedthats...neatadistance.Over10,000participantssenthealingint...aquantitative-EEG.Thedatawasanalyzedbyworldexperts...C.Adaminitiatedtheworld,slargestintentionalhealing...ofaspecificvisualizationtobeusedbyallparticipants,...
(Date:11/24/2009)...de accurate preliminary interpretation of emergenc...ng neuroradiologist unavailable, according to resu... center published in the December issue of the Jo... ). , The accuracy of image interpretation is t... In most training programs, radiology residents pr...
(Date:11/24/2009)...wire/--OnFriday,November20,juniorfeatherweightboxe...adduringatitleboutinPhiladelphia.HewasrushedtoHahn...onducted,hewasdeclaredbraindeadonSunday. ,, Gif...rganization(OPO)servingeasternPennsylvania,souther...partofstandardclinicalprocedurestodetermineifFranc...
(Date:11/24/2009)...re/--SkyFoundation,Inc.,anon-profitfoundationdedic...testfortheearlydetectionofpancreaticcancer,todayan...ninJune2008.TheannouncementwasmadebySheilaSkyKassl...irstmajorfundraiser. ,, Thefoundationhelditsfir...ClubinBloomfieldHills,Mich.Guestsheardfromspeakers...
Breaking Medicine News(10 mins):Health News:Oklahoma Thunder Inserts HydroWorx into Line-Up at Integris Health Center 2Health News:Oklahoma Thunder Inserts HydroWorx into Line-Up at Integris Health Center 3Health News:Intriguing Scientific Results from World's Largest Intention Healing Project: DreamHealer 2Health News:Paying Tribute to Boxer Francisco 'Paco' Rodriguez 2Health News:Sky Foundation, Inc. Raises More Than $100,000 to Find a Test for Early Detection of Pancreatic Cancer 2
...idiopathic pulmonary fibrosis. This disease is inc...g// in the lungs, which often leads to a lung tran...journal Chest, the research shows that more than h...test to measure lung function. "Over five mi...
... communication channel between the human brain and...of electrophysiological signals like the Electroen...e BCI system detects such changes and transforms i... enable completely paralyzed patients (locked-in s...
..., the third leading cause of infant death, may be ... to an article in Nursing for Women’s Health, neon...parents on the potential benefits of using a pacif...pacifier use be encouraged for children less than ...
...t and dairy products from cloned animals// are saf...ty (EFSA) was asked by the European Commission to ... At present, there is no specific regulati...s from cloned animals were safe. It has pu...
...r in Bihar with seven new cases detected this year... a state that has vowed to eradicate it by 2007-en...o cases surfaced in the state till the first week ...wo in Muzaffarpur and one each in Supaul and Rohta...
... serious risks of injury and even death from needl... As lung cancer is the leading cause of cancer de...hat early detection and treatment could save lives...d the study, said conclusively, “We don’t think th...
Other Medicine News:Health News:Viagra Helps Patients With Idiopathic Pulmonary Fibrosis 2Health News:EU to Look at Cloned Meat Safety 2Health News:Seven Polio Cases Detected in Bihar 2Health News:CT Scans may Not Benefit Lung Cancer Patients 2
AP250 Auto Chart Projector
ResMed VPAP III ST
...entilator is a blower-based, bi-level positive pre...ously breathing patients weighing 30 kg or more. T... insufficiency and/or obstructive sleep apnea in t...The KnightStar 330 Ventilator includes a 3-30 cm H...
GoodKnight® 425 Bi-Level® Device
Medicine Products: